Sensus Healthcare, Inc. (SRTS)
| Market Cap | 60.34M |
| Revenue (ttm) | 9.58M |
| Net Income (ttm) | -6.84M |
| Shares Out | 16.43M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | 357.14 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $3.66 |
| Previous Close | $3.38 |
| Change ($) | 0.28 |
| Change (%) | 8.28% |
| Day's Open | 3.38 |
| Day's Range | 3.22 - 3.73 |
| Day's Volume | 67,471 |
| 52-Week Range | 1.76 - 6.09 |
BOCA RATON, Fla, March 08, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effectiv...
Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices Patent covers beam splitting and sculpting capabilit...
BOCA RATON, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective...
Sensus Healthcare' (SRTS) CEO Joe Sardano on Q3 2020 Results - Earnings Call Transcript
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
BOCA RATON, Fla, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective ...
BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and ...
Sensus Healthcare' (SRTS) CEO Joe Sardano on Q2 2020 Results - Earnings Call Transcript
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems
Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state
BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological a...
BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effect...
BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and ...
BOCA RATON, Fla. , June 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and...
BOCA RATON, Fla, June 24, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non...
June 18 Event is the Third in a Series of Topical Discussions
Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q1 2020 Results - Earnings Call Transcript
Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT
Sensus Healthcare's (SRTS) CEO Joe Sardano on Q4 2019 Results - Earnings Call Transcript
BOCA RATON, Fla, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effectiv...
New corporate structure positions company for 2020 financial goals
BOCA RATON, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effe...
Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q3 2019 Results - Earnings Call Transcript
Sensus Healthcare's (SRTS) CEO Joe Sardano on Q2 2019 Results - Earnings Call Transcript
Sensus Healthcare's (SRTS) CEO Joe Sardano on Q1 2019 Results - Earnings Call Transcript
Today, we look at a small medical device maker based in South Florida.
About SRTS
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and do... [Read more...]
| Industry Medical Devices | IPO Date Jun 3, 2016 |
| CEO Joseph Sardano | Employees 42 |
| Stock Exchange NASDAQ | Ticker Symbol SRTS |
Financial Performance
In 2020, SRTS's revenue was $9.58 million, a decrease of -64.87% compared to the previous year's $27.26 million. Losses were -$6.84 million, 302.1% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for SRTS stock is "Buy." The 12-month stock price forecast is 6.71, which is an increase of 83.33% from the latest price.